0000899243-23-012900.txt : 20230512
0000899243-23-012900.hdr.sgml : 20230512
20230512200339
ACCESSION NUMBER: 0000899243-23-012900
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230511
FILED AS OF DATE: 20230512
DATE AS OF CHANGE: 20230512
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ghosh Anirvan
CENTRAL INDEX KEY: 0001807437
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38470
FILM NUMBER: 23917910
MAIL ADDRESS:
STREET 1: C/O UNITY BIOTECHNOLOGY, INC.
STREET 2: 285 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Unity Biotechnology, Inc.
CENTRAL INDEX KEY: 0001463361
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 264726035
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 285 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 416-1192
MAIL ADDRESS:
STREET 1: 285 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: Cenexys, Inc.
DATE OF NAME CHANGE: 20130703
FORMER COMPANY:
FORMER CONFORMED NAME: Forge Inc
DATE OF NAME CHANGE: 20090504
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-05-11
0
0001463361
Unity Biotechnology, Inc.
UBX
0001807437
Ghosh Anirvan
C/O UNITY BIOTECHNOLOGY, INC.
285 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
Chief Executive Officer
0
Stock Option (Right to Buy)
2.77
2023-05-11
4
A
0
135000
2.77
A
2033-05-11
Common Stock
135000
135000
D
Stock Option (Right to Buy)
29.40
2023-05-11
4
D
0
24999
0.00
D
2030-09-13
Common Stock
24999
0
D
Stock Option (Right to Buy)
2.77
2023-05-11
4
A
0
24999
0.00
A
2030-09-13
Common Stock
24999
24999
D
Stock Option (Right to Buy)
59.75
2023-05-11
4
D
0
15000
0.00
D
2031-01-29
Common Stock
15000
0
D
Stock Option (Right to Buy)
2.77
2023-05-11
4
A
0
15000
0.00
A
2031-01-29
Common Stock
15000
15000
D
Stock Option (Right to Buy)
41.80
2023-05-11
4
D
0
29000
0.00
D
2031-06-24
Common Stock
29000
0
D
Stock Option (Right to Buy)
2.77
2023-05-11
4
A
0
29000
0.00
A
2031-06-24
Common Stock
29000
29000
D
Stock Option (Right to Buy)
10.60
2023-05-11
4
D
0
56666
0.00
D
2032-02-09
Common Stock
56666
0
D
Stock Option (Right to Buy)
2.77
2023-05-11
4
A
0
56666
0.00
A
2032-02-09
Common Stock
56666
56666
D
The underlying shares vest and become exercisable pursuant to the following schedule: One-eighth of the shares subject to the option vest in successive, equal quarterly installments starting on August 11, 2023, subject to the Reporting Person's continued service to Issuer through the applicable vesting date.
The underlying shares vest and become exercisable pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on September 13, 2021 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
On May 11, 2023, the option originally granted to the Reporting Person on September 13, 2020 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.
The underlying shares vest and become exercisable pursuant to the following schedule: Twenty five percent (25%) of the shares subject to the option vested on January 29, 2022 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
On May 11, 2023, the option originally granted to the Reporting Person on January 29, 2021 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.
Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on June 24, 2021 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
On May 11, 2023, the option originally granted to the Reporting Person on June 24, 2021 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.
The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
On May 11, 2023, the option originally granted to the Reporting Person on February 9, 2022, was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.
/s/ Alexander Nguyen, Attorney-in-Fact for Anirvan Ghosh
2023-05-12